"Probenecid" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The prototypical uricosuric agent. It inhibits the renal excretion of organic anions and reduces tubular reabsorption of urate. Probenecid has also been used to treat patients with renal impairment, and, because it reduces the renal tubular excretion of other drugs, has been used as an adjunct to antibacterial therapy.
| Descriptor ID |
D011339
|
| MeSH Number(s) |
D02.065.884.625 D02.886.590.700.625
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Probenecid".
Below are MeSH descriptors whose meaning is more specific than "Probenecid".
This graph shows the total number of publications written about "Probenecid" by people in this website by year, and whether "Probenecid" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 0 | 1 | 1 |
| 2002 | 0 | 1 | 1 |
| 2021 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Probenecid" by people in Profiles.
-
Assessment of drug transporters involved in the urinary secretion of [99mTc]dimercaptosuccinic acid. Nucl Med Biol. 2021 Mar-Apr; 94-95:92-97.
-
Novel role of transient receptor potential vanilloid 2 in the regulation of cardiac performance. Am J Physiol Heart Circ Physiol. 2014 Feb 15; 306(4):H574-84.
-
Evaluation of the clinical relevance of the expression and function of P-glycoprotein, multidrug resistance protein and lung resistance protein in patients with primary acute myelogenous leukemia. Leuk Res. 2002 Feb; 26(2):143-54.
-
Co-administration of probenecid, an inhibitor of a cMOAT/MRP-like plasma membrane ATPase, greatly enhanced the efficacy of a new 10-deazaaminopterin against human solid tumors in vivo. Clin Cancer Res. 2000 Sep; 6(9):3705-12.
-
Methotrexate distribution within the subarachnoid space after intraventricular and intravenous administration. Cancer Chemother Pharmacol. 2000; 45(3):259-64.
-
Probenecid inhibition of methotrexate cytotoxicity in mouse L1210 leukemia cells. Cancer Treat Rep. 1984 Mar; 68(3):521-5.
-
Active transport of methotrexate from cerebrospinal fluid in humans. Cancer Res. 1980 Jul; 40(7):2184-7.